Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting immunostaining in relation to complex human pathologies.TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding. Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
MARK3, a MARK type protein kinase, was originally identified as a marker induced with DNA damaging agents. The protein contains a N-terminal kinase domain. It has been shown to bind and phosphorylate CDC25C and to regulate Ras signaling by phosphorylating the MAPK scaffold, KSR1. At least three mRNA transcripts have been reported -- 3.0-, 3.1-, and 3.8-kb. Loss of MARK3 has been associated with carcinogenesis in the pancreas.
|Gene Name:||MAP/microtubule affinity-regulating kinase 3|
|Family/Subfamily:||Protein Kinase , MARK|
|Synonyms:||MARK3, C-TAK1, ELKL motif kinase 2, EMK2, Etk-1, KP78, PAR1A, Ser/Thr protein kinase PAR-1, Par-1a, CTAK1, EMK-2, Protein kinase STK10|
|Target Sequences:||NM_002376 NP_002367.5 P27448|
If you do not find the reagent or information you require, please contact Customer.Support@LSBio.com to inquire about additional products in development.